Business / Finance

RSS

Cephalon files definitive Consent Revocation Statement, recommends shareholders to reject Valeant's proposals

Cephalon, Inc. today announced that it has filed a definitive Consent Revocation Statement with the Securities and Exchange Commission (SEC) urging shareholders to reject Valeant Pharmaceuticals International Inc.'s proposals to remove Cephalon's entire Board of Directors and replace them with nominees hand-picked by Valeant.

22 Apr 2011

Prism Medical first quarter revenue increases 32% to $1.8 million

Prism Medical Ltd., a leading provider of durable medical equipment and related services to the mobility challenged, today reported financial results for the three months ended February 28, 2011.

22 Apr 2011

UHT net income is $4.1 million for quarter ended March 31, 2011

Universal Health Realty Income Trust announced today that for the quarter ended March 31, 2011, net income was $4.1 million, or $.33 per diluted share, as compared to $4.5 million, or $.37 per diluted share, during the same quarter in the prior year.

22 Apr 2011

Endologix total revenue increases 28% to $18.5 million for first quarter 2011

Endologix, Inc., developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.

22 Apr 2011

Sonomax net revenue decreases to $642,766 for year ended December 31, 2010

Sonomax Technologies Inc. today disclosed its results for the year ended December 31, 2010.

22 Apr 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.

21 Apr 2011

Life Time Fitness first quarter revenue increases 9.5% to $240.6 million

Life Time Fitness, Inc., The Healthy Way of Life Company, today reported its financial results for the first quarter ended March 31, 2011.

21 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Meridian Bioscience second quarter net sales increases 32% to $41.1 million

Meridian Bioscience, Inc., today reported fiscal 2011 second quarter and six months net sales of $41.1 million and $78.3 million, respectively, increases of 32% and 6%, respectively, from the same periods of the prior fiscal year;

21 Apr 2011

UnitedHealth Group's consolidated first quarter 2011 revenues increased 10% year-over-year

UnitedHealth Group today reported first quarter results, highlighted by accelerated revenue growth from both its UnitedHealthcare and Optum businesses.

21 Apr 2011

Baxter’s first quarter global sales increase 12% to $3.3 billion

Baxter International Inc. today announced strong financial results for the first quarter of 2011, and raised its outlook for full-year 2011.

From Baxter International Inc. 21 Apr 2011

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three months ended March 31, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $166.1 million, reflecting steady additions of new patients, compared to $117.6 million for the same period in 2010.

21 Apr 2011

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.

21 Apr 2011

LabCorp first quarter revenues increase 14.6% to $1,368.4 million

Laboratory Corporation of America® Holdings today announced results for the quarter ended March 31, 2011. These results include the operations of Genzyme Genetics, which the Company acquired in the fourth quarter of 2010.

21 Apr 2011

Covidien second quarter net sales up 10% to $2.80 billion

Covidien plc today reported results for the second quarter of fiscal 2011 (January - March 2011). Net sales of $2.80 billion increased 10% from the $2.55 billion reported in the second quarter a year ago. Foreign exchange rate movement added approximately two percentage points to the quarterly sales growth rate.

21 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

ICON first quarter net revenue increases 4.6% to $229 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2011.

21 Apr 2011

KellBenx secures $2.5 million from initial funding round

KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has secured an initial funding round of $2.5 million from four investors – three biotechnology venture capital groups and one angel investor. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.

21 Apr 2011

BSD Medical sells hyperthermia systems to a U.S. Government medical facility

BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that a U.S. Government medical facility has purchased a BSD-500 Hyperthermia System (BSD-500).

21 Apr 2011